Impact of Orlistat-Induced Weight Loss on Diastolic Function and Heart Rate Variability in Severely Obese Subjects with Diabetes
Table 1
Baseline characteristics of type 2 diabetic severely obese subjects before and after treatment.
Control group
Treatment group
Pre
Post
Pre
Post
N
13
13
16
16
Age (years)
48 ± 11
—
47 ± 9
—
Duration of diabetes (years)1, 3
4.8 ± 4.6
—
7.2 ± 6.1
—
Men/Women (number)
7/6
7/6
7/9
7/9
Weight (kg)
142.6 ± 34.6
142.1 ± 35.0
129.6 ± 17.4
125.9 ± 17.5*‡
BMI (kg/m2)
51.2 ± 9.2
51.2 ± 9.0
45.9 ± 7.3
44.8 ± 7.5*‡
Waist circumference (cm)
145.8 ± 20.8
144.3 ± 20.6
138.4 ± 14.7
133.9 ± 17.0*
Fat percentage (%)2
48.5 ± 5.4
48.8 ± 4.1
45.7 ± 8.3
45.6 ± 8.7
Fat mass (kg)2
67.3 ± 13.6
66.2 ± 13.8
59.1 ± 13.1
57.4 ± 13.5
Fat free mass (kg)2
72.3 ± 18.9
70.0 ± 17.8
70.4 ± 15.4
68.5 ± 15.2*
Resting HR (beat/min)
83 ± 7
84 ± 12
80 ± 12
78 ± 11
SBP (mmHg)
127 ± 20
126 ± 15
137 ± 18
127 ± 13
DBP (mmHg)
71 ± 10
70 ± 9
74 ± 12
70 ± 11
Fasting glycemia (mmol/L)1, 3
8.0 ± 2.5
8.1 ± 2.5
7.9 ± 3.0
6.7 ± 2.2*
HbA1c (%)1
7.3 ± 1.1
6.7 ± 0.9*
7.3 ± 2.1
6.6 ± 1.3*
Total cholesterol4
4.8 ± 0.8
4.7 ± 0.7
4.5 ± 0.7
4.3 ± 0.8
HDL-cholesterol (mmol/L)4
1.3 ± 0.2
1.2 ± 0.3
1.2 ± 0.3
1.2 ± 0.3
LDL-cholesterol (mmol/L)4
2.7 ± 0.8
2.5 ± 0.7*
2.5 ± 0.6
2.2 ± 0.8*
Triglyceride (mmol/L)4
1.8 ± 0.5
2.0 ± 0.7
1.7 ± 0.6
1.9 ± 0.8
Mean ± standard deviation; *: pre versus post; ‡: control versus treatment; BMI: Body mass index; DBP: Diastolic blood pressure; HR: Heart rate; MBP: Mean blood pressure; SBP: Systolic blood pressure. 1One subject missing in the control group. 2Two subjects missing in the control group. 3One subject missing in the treatment group. 4Two subjects missing in the treatment group.
